<?xml version="1.0" encoding="UTF-8"?>
<ref id="B112">
 <label>112</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Triplitt</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Solis-Herrera</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Cersosimo</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Abdul-Ghani</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Defronzo</surname>
    <given-names>R. A.</given-names>
   </name>
  </person-group>
  <article-title>Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus</article-title>
  <source>
   <italic toggle="yes">Expert Opinion on Pharmacotherapy</italic>
  </source>
  <year>2015</year>
  <volume>16</volume>
  <issue>18</issue>
  <fpage>2819</fpage>
  <lpage>2833</lpage>
  <pub-id pub-id-type="doi">10.1517/14656566.2015.1114098</pub-id>
  <pub-id pub-id-type="other">2-s2.0-84952717693</pub-id>
  <pub-id pub-id-type="pmid">26583910</pub-id>
 </element-citation>
</ref>
